Visikol Revenue and Competitors
Estimated Revenue & Valuation
- Visikol's estimated annual revenue is currently $3.3M per year.
- Visikol's estimated revenue per employee is $333,200
Employee Data
- Visikol has 10 Employees.
- Visikol grew their employee count by -57% last year.
Visikol's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Associate Director In Vitro and Histology | Reveal Email/Phone |
2 | Office Manager | Reveal Email/Phone |
3 | Human Resource Manager | Reveal Email/Phone |
4 | Associate Scientist | Reveal Email/Phone |
5 | Business Development Lead | Reveal Email/Phone |
6 | Scientist | Reveal Email/Phone |
7 | Scientist | Reveal Email/Phone |
8 | Senior Lead Image Analyst | Reveal Email/Phone |
Visikol Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $3.3M | 10 | -57% | N/A | N/A |
#2 | $2.6M | 23 | 28% | N/A | N/A |
What Is Visikol?
Visikol is a contract research organization that is focused on transforming tissues into insights through the use of digital image analysis and advanced optical imaging. The company offers services to pharmaceutical companies in the areas of in vitro assays, digital pathology and whole mount tissue imaging. The team at Visikol are experts in advanced 3D cell culture models (e.g. organoids, spheroids, microtissues), developing customized image analysis solutions and high-throughput imaging (e.g. high content screening). Visikol also provides a suite of products and kits for use in advanced 3D tissue imaging.
keywords:N/A
N/A
Total Funding
10
Number of Employees
$3.3M
Revenue (est)
-57%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Visikol News
BICO Group AB(Visikol); CN Bio Innovations Limited; Elveflow; Emulate, Inc. AxoSim Technologies LLC; Nortis Inc. Tara Biosystems...
Other Companies in Hampton
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 12 | 0% | N/A |
#2 | $0.5M | 12 | 71% | N/A |
#3 | $1.3M | 12 | -14% | N/A |
#4 | $1.7M | 12 | -14% | N/A |
#5 | $2.5M | 13 | 0% | N/A |